FrancophonIA/ELRC3.0 huggingface dataset:
English: • coccidioidomycosis (fungal infection of the lungs caused by breathing in spores).
Maltese: • koċċidioidomikożi (infezzjoni fungali tal-pulmun ikkawżata mit-teħid ta' skald man-nifs).
English: For the treatment and prevention of fungal infections, the recommended dose of Noxafil tablets or Noxafil solution for infusion is 300 mg twice a day on the first day followed by 300 mg once a day thereafter; the duration of treatment depends on the severity of the disease and the patient's response.
Maltese: Għall-kura u l-prevenzjoni ta' infezzjonijiet fungali, id-doża rakkomandata tal-pilloli Noxafil jew issoluzzjoni Noxafil għal infużjoni hija ta' 300 mg darbtejn kuljum fl-ewwel ġurnata segwiti minn 300 mg darba kuljum minn dakinhar 'il hemm; it-tul ta' żmien tal-kura jiddependi minn kemm hi severa lmarda u r-rispons tal-pazjent.
English: For the treatment of fungal infections, with the exception of oral candidiasis, Noxafil oral suspension is taken at a dose of 400 mg (10 ml) twice a day, or 200 mg (5 ml) four times a day in patients who cannot tolerate a meal.
Maltese: Għall-kura ta' infezzjonijiet fungali, bl-eċċezzjoni ta' kandidjażi orali, is-sospensjoni orali Noxafil tittieħed f'doża ta' 400 mg (10 ml) darbtejn kuljum, jew 200 mg (5 ml) erba' darbiet kuljum f'pazjenti li ma jittollerawx ikla.
English: It works by preventing the formation of ergosterol, which is an important part of fungal cell walls.
Maltese: Din taħdem billi tipprevjeni l-formazzjoni ta' ergosterol, li huwa parti importanti mill-ħitan taċċelloli fungali.
English: For the full list of all side effects reported with Noxafil, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji rrapportati b'Noxafil, ara l-fuljett ta' tagħrif.
English: The ability to prevent infections was investigated in two additional main studies, where Noxafil oral suspension was compared with fluconazole in 600 stem cell transplant patients and with fluconazole or itraconazole in 602 patients with blood or bone marrow cancer.
Maltese: L-abbiltà li jiġu pprevenuti infezzjonijiet kienet investigata f'żewġ studji prinċipali addizzjonali, fejn issospensjoni orali Noxafil tqabblet ma' flukonażol f'600 pazjent li kellhom trapjant ta' ċelloli staminali u ma' flukonażol jew itrakonażol f'602 pazjenti b'kanċer tad-demm jew tal-mudullun.
English: Noxafil oral suspension is also used as a first-line treatment for ‘thrush', a fungal infection of the mouth and throat due to Candida.
Maltese: Is-sospensjoni orali Noxafil tintuża wkoll bħala kura tal-ewwel għażla għal 'tikek bojod' (thrush), infezzjoni fungali tal-ħalq u l-gerżuma minħabba Candida.
English: • Noxafil oral suspension is taken with a meal or nutritional supplement; the suspension must be shaken well before use.
Maltese: • Is-sospensjoni orali Noxafil tittieħed mal-ikel jew ma' suppliment nutrittiv; is-sospensjoni għandha tiġi mħallta sew qabel tintuża.
English: The results obtained with Noxafil were compared with the records of 218 patients who were treated with other antifungal medicines.
Maltese: Ir-riżultati miksubin b'Noxafil tqabblu mar-rekords ta' 218-il pazjent li ħadu l-kura b'mediċini antifungali oħrajn.
English: A risk management plan has been developed to ensure that Noxafil is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jiżgura li Noxafil jintuża bl-aktar mod sigur possibbli.
English: How has Noxafil been studied?
Maltese: Kif ġie studjat Noxafil?
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Flexicam on 10 April 2006 and an extension to Flexicam 5mg/ml solution for injection on 9 December 2008.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Flexicam fl-10 ta' April 2006 u estensjoni għal Flexicam 5 mg/ml f'soluzzjoni għal injezzjoni fid-9 ta' Diċembru 2008.
English: Flexicam is a ‘generic': this means that Flexicam is similar to a ‘reference veterinary medicine' already authorised in the EU (Metacam 1.5 mg/ml oral suspension).
Maltese: Flexicam huwa ‘mediċina ġenerika': dan ifisser li Flexicam huwa simili għal ‘mediċina veterinarja ta' referenza' li hija diġà awtorizzata fl-UE (Metacam 1.5 mg/ml sospensjoni orali).
English: Why has Flexicam been approved?
Maltese: Għaliex ġie approvat Flexicam?
English: This summary was last updated in November 2011.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'Novembru 2011.
English: Meloxicam acts by inhibition of prostaglandin synthesis.
Maltese: Il-meloxikam taġixxi billi xxekkel is-sinteżi tal-prostaglandini.
English: What is the risk associated with Flexicam?
Maltese: Għal xiex jintuża Flexicam?
English: Presentations of Flexicam oral suspension were subsequently not renewed.
Maltese: Sussegwentement il-preżentazzjonijiet ta' Flexicam f'sospensjoni orali ma ġġeddux.
English: If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part
Maltese: Jekk tixtieq iktar informazzjoni relatata mar-rakkomandazzjonijiet tas-CVMP, aqra d-Diskussjoni Xjentifika (ukoll parti mill-EPAR).
English: Occasional side effects of Flexicam are those seen with NSAIDs, such as loss of appetite, vomiting, diarrhoea, blood appearing in the stools and apathy (lack of vitality).
Maltese: Bi Flexicam ġieli ġew osservati effetti sekondarji tipiċi tal-NSAIDs, bħal telf tal-aptit, remettar, dijarrea, demm fil-feċi u apatija (nuqqas ta' vitalità).
English: The CVMP concluded that the benefits of Flexicam exceed the risks for the alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders, reduction of postoperative pain and inflammation following orthopaedic and soft tissue surgery in dogs and reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery in cats and recommended that Flexicam be given a marketing authorisation.
Maltese: IsCVMP ikkonkluda li l-benefiċċji ta' Flexicam huma akbar mir-riskji fis-serħan tal-infjammazzjoni u taluġigħ f'disturbi muskoluskeletriċi kemm akuti kif ukoll kroniċi u fit-tnaqqis tal-uġigħ postoperatorju u infjammazzjoni wara interventi kirurġiċi ortopediċi u fuq t-tessuti rotob fil-klieb u fit-tnaqqis tal-uġigħ postoperatorju wara ovarjoisterektomija u interventi minuri fuq it-tessuti rotob fil-qtates u rrakkomanda li Flexicam jingħata awtorizzazzjoni għat-tqegħid fis-suq.
English: Flexicam contains meloxicam, which belongs to a class of medicines called non-steroidal antiinflammatory drugs (NSAIDs).
Maltese: Flexicam fih il-meloxikam li jappartieni lill-klassi ta' mediċini msejħin mediċini antinfjammatorji mhux sterojdali (NSAIDs).
English: Cats: Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.
Maltese: Għat-tnaqqis tal-uġigħ postoperatorju wara ovarjoisterektomija u interventi kirurġiċi minuri fuq it-tessuti rotob.
English: Flexicam is efficacious in alleviating the inflammation and pain in both acute and chronic musculoskeletal disorders and reducing the post operative pain following orthopaedic and soft tissue surgery in dogs and in reducing the post-operative pain after ovariohysterectomy and minor soft tissue surgery in
Maltese: Intwera li Flexicam huwa effikaċi fis-serħan tal-infjammazzjoni u tal-uġigħ f'disturbi muskoluskeletriċi kemm akuti u kemm kroniċi u fit-tnaqqis tal-uġigħ postoperatorju wara interventi kirurġiċi ortopediċi u fuq t-tessuti rotob fil-klieb u fit-tnaqqis tal-uġigħ postoperatorju wara ovarjoisterektomija u interventi kirurġiċi minuri fuq it-tessuti rotob fil-qtates.
English: Studies have been carried out to prove that Flexicam is ‘bioequivalent' to the reference veterinary medicine: this means that Flexicam is equivalent to Metacam 1.5 mg/ml suspension in the way it is absorbed and used by the body.
Maltese: Saru studji biex juru li Flexicam huwa ‘bijoekwivalenti' għall-mediċina veterinarja ta' referenza: dan ifisser li Flexicam huwa ekwivalenti għas-sospensjoni Metacam 1.5 mg/ml fil-mod kif jiġi assorbit u użat mill-ġisem.
English: Flexicam was presented as a pale green oral suspension (1.5mg/ml) for dogs (to be given mixed with food) and a yellow solution for injection (5mg/ml) for dogs and cats.
Maltese: Flexicam jiġi f'sospensjoni orali ta' lewn aħdar ċar (1.5 mg/ml) għall-klieb (li għandu jingħata mħallat mal-ikel) u soluzzjoni għal injezzjoni safra (5 mg/ml) għall-klieb u l-qtates.
English: Flexicam contains meloxicam which belongs to a class of medicines having anti-inflammatory action.
Maltese: Flexicam fih is-sustanza attiva meloxicam li tappartieni lill-klassi ta' mediċini li jaġixxu kontra linfjammazzjonijiet.
English: Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders and reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.
Maltese: Klieb: Għas-serħan mill-infjammazzjoni u minn uġigħ f'disturbi muskoluskeletriċi kemm akuti u kemm kroniċi u għat-tnaqqis tal-uġigħ postoperatorju u tal-infjammazzjoni wara interventi kirurġiċi ortopediċi u fuq it-tessuti rotob.
English: In very rare cases, they may be serious or fatal.
Maltese: F'każi rari ħafna jistgħu jkunu serji jew fatali.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) considered that, in accordance with European Union requirements, Flexicam has been shown to be bioequivalent to Metacam 1.5 mg/ml oral suspension.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu Veterinarju (CVMP) qies li, skont ir-rekwiżiti tal-Unjoni Ewropea, intwera li Flexicam huwa bijoekwivalenti għal Metacam 1.5 mg/ml f'sospensjoni orali.
English: The full EPAR for Febuxostat Mylan can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Febuxostat Mylan contains the active substance febuxostat and is a ‘generic medicine'.
Maltese: Febuxostat Mylan fih is-sustanza attiva febuxostat u huwa ‘mediċina ġenerika'.
English: Febuxostat Mylan febuxostat
Maltese: Informazzjoni oħra dwar Febuxostat Mylan
English: Febuxostat Mylan is available as tablets (80 and 120 mg) and can only be obtained with a prescription.
Maltese: Febuxostat Mylan ji ġi bħala pilloli (80 u 120 mg
English: This is a summary of the European public assessment report (EPAR) for Febuxostat Mylan.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Febuxostat Mylan.
English: This can reduce the symptoms of gout.
Maltese: Dan jista' jnaqqas is-sintomi tal-gotta.
English: EPAR summary for the public
Maltese: Sommarju tal-EPAR għall-pubbliku febuxostat
English: Why is Febuxostat Mylan approved?
Maltese: Għaliex ġie approvat Febuxostat Mylan?
English: Febuxostat Mylan is used in patients who have signs of a build-up of crystals, including gouty arthritis (pain and inflammation in the joints) or tophi (‘stones', larger deposits of urate crystals that can cause joint and bone damage).
Maltese: Febuxostat Mylan jintuża f'pazjenti li jkollhom sinjali ta' akkumulazzjoni ta' kristalli, inkluż l-artrite gotta (uġigħ u infjammazzjoni fil-ġogi) jew tofi, ('ġebla', depożiti akbar ta' kristalli tal-urat li jistgħu jikkawżaw ħsara fil-ġogi u fl-għadam).
English: Febuxostat Mylan is also used to treat and prevent high levels of uric acid in the blood in adults with blood cancers who are receiving chemotherapy (medicines to treat cancer) and at risk of tumour lysis syndrome (a complication due to the breakdown of cancer cells causing a sudden rise of uric acid in the blood which can cause damage to the kidneys).
Maltese: Febuxostat Mylan jintuża wkoll għall-kura u għall-prevenzjoni ta' livelli għoljin ta' aċidu uriku fid-demm f'adulti b'kanċer fid-demm li jkunu qed jingħataw kimoterapija (mediċini għall-kura tal-kanċer) u li jkunu qegħdin f'riskju tas-sindromu tat-tumur ta' lisi (kumplikazzjoni kkawżata mit-tkissir ta' ċelloli talkanċer li jikkawża żieda f'salt tal-aċidu uriku fid-demm li tista' tikkawża ħsara lill-kliewi).
English: For the treatment of long-term hyperuricaemia, the recommended dose of Febuxostat Mylan is 80 mg once a day.
Maltese: Għall-kura ta' iperuriċemija fit-tul, id-doża rakkomandata ta' Febuxostat Mylan hija ta' 80 mg darba kuljum.
English: Because Febuxostat Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Minħabba li Febuxostat Mylan huwa mediċina ġenerika u bijoekwivalenti għall-mediċina ta' referenza, il-benefiċċji u r-riskji tiegħu jitqiesu l-istess bħal dawk tal-mediċina ta' referenza.
English: This usually reduces blood uric acid levels within two weeks, but the dose can be increased to 120 mg once a day if blood uric acid levels remain high (above 6 mg per decilitre) after two to four weeks.
Maltese: Normalment dan inaqqas il-livelli ta' aċidu uriku fid-demm fi żmien ġimagħtejn, iżda d-doża tista' tiżdied għal 120 mg darba kuljum jekk il-livelli ta' aċidu uriku fid-demm jibqgħu għoljin ('il fuq minn 6 mg kull deċilitru) wara perjodu ta' bejn ġimagħtejn u erba' ġimgħat.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Febuxostat Mylan has been shown to have comparable quality and to be bioequivalent to Adenuric.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) tal-Aġenzija kkonkluda li, b'mod konformi mar-rekwiżiti tal-UE, Febuxostat Mylan wera li għandu kwalità komparabbli u huwa bijoekwivalenti għal Adenuric.
English: The Committee recommended that Febuxostat Mylan be approved for use in the EU.
Maltese: Il-Kumitat irrakkomanda li Febuxostat Mylan ikun approvat għall-użu fl-UE.
English: Other information about Febuxostat Mylan
Maltese: Kif jintuża Febuxostat Mylan?
English: It works by blocking an enzyme called xanthine oxidase, which is needed to make uric acid in the body.
Maltese: Taħdem billi timblokka enzim magħruf bħala ksantinossidażi (xanthine oxidase), li huwa meħtieġ biex jiġi prodott laċidu uriku fil-ġisem.
English: What are the benefits and risks of Febuxostat Mylan?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' Febuxostat Mylan?
English: This means that Febuxostat Mylan contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Adenuric.
Maltese: Dan ifisser li Febuxostat Mylan fih l-istess sustanza attiva u jaħdem bl-istess mod bħal ‘mediċina ta' referenza' li hija diġà awtorizzata fl-Unjoni Ewropea (EU) bl-isem ta' Adenuric.
English: The active substance in Febuxostat Mylan, febuxostat, reduces the formation of uric acid.
Maltese: Is-sustanza attiva f'Febuxostat Mylan, feboxustat, tnaqqas il-formazzjoni tal-aċidu uriku.
English: For the prevention and treatment of hyperuricaemia in patients undergoing chemotherapy, the recommended dose is 120 mg once a day.
Maltese: Għall-prevenzjoni u l-kura ta' iperuriċemija f'pazjenti li jkunu qegħdin jieħdu l-kimoterapija, id-doża rakkomandata hija ta' 120 mg darba kuljum.
English: Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Adenuric, and do not need to be repeated for Febuxostat Mylan.
Maltese: referenza, Adenuric, u ma għandhomx għalfejn jiġu ripetuti għal Febuxostat Mylan.
English: Febuxostat Mylan is a medicine used to treat adults with long-term hyperuricaemia (high levels of uric acid or ‘urate' in the blood).
Maltese: Febuxostat Mylan huwa mediċina li tintuża fil-kura ta' adulti b'iperuriċemija fit-tul (livelli għoljin ta' aċidu uriku jew ‘urat' fid-demm).
English: By reducing the production of uric acid, Febuxostat Mylan can reduce levels of uric acid in the blood and keep them low, stopping crystals from building up.
Maltese: Billi jnaqqas il-produzzjoni tal-aċidu uriku, Febuxostat Mylan jista' jbaxxi l-livelli ta' aċidu uriku fid-demm u jżommhom baxxi, u jwaqqaf il-kristalli milli jakkumulaw.
English: MA (EU) number (Invented) name
Maltese: Numru MA (UE)
English: Pack size
Maltese: Pakkett Li Jmiss MalProdott
English: Jetrea ocriplasmin
Maltese: Jetrea okriplasmina
English: The full EPAR for Jetrea can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: After 28 days, the results were that adhesions had cleared in 25% and 28% of patients who were given Jetrea injection (61 out of 219 and 62 out of 245), compared with 13% and 6% of those who received placebo (14 out of 107 and 5 out of 81).
Maltese: Wara 28 jum, ir-riżultati kienu tali li l-adeżjonijiet għebu f'25% u fi 28% tal-pazjenti li ngħataw injezzjoni ta' Jetrea (61 minn 219 u 62 minn 245), meta mqabbla ma' 13% u 6% ta' dawk li ngħataw il-plaċebo (14 minn 107 u 5 minn 81).
English: It contains the active substance ocriplasmin.
Maltese: Fih is-sustanza attiva okriplasmina.
English: Why is Jetrea approved?
Maltese: Għaliex ġie approvat Jetrea?
English: This is a summary of the European public assessment report (EPAR) for Jetrea.
Maltese: Dan id-dokument huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Jetrea.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Jetrea on 13 March 2013.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea għal Jetrea fit-13 ta' Marzu 2013.
English: In two main studies involving 652 adults with vitreomacular adhesion and decreased vision, patients were given a single intravitreal injection of 0.125 mg Jetrea or a placebo injection (a dummy treatment).
Maltese: F'żewġ studji ewlenin fuq 652 adult b'adezjoni vitreomakulari u b'vista mnaqqsa, il-pazjenti ngħataw injezzjoni intravitreali waħda ta' 0.125 mg ta' Jetrea jew injezzjoni plaċebo (kura finta).
English: The most common side effects are vitreous floaters (small, often irregular, dark shapes in the field of vision), eye pain, photopsia (flashes of light in the field of vision) and chromatopsia (changes in colour perception), as well as conjunctival haemorrhage (bleeding of the membrane that lies over the white part of the eye).
Maltese: L-effetti sekondarji l-aktar komuni huma depożiti vitriji (forom żgħar u skuri, spiss irregolari, fil-kamp viżiv), uġigħ fl-għajn, fotopsja (leħħiet ta' dawl fil-kamp viżiv) u kromatopsja (bidliet fil-perċezzjoni tal-kulur), kif ukoll emorraġija konġuntivali (fsada tal-membrana mimduda fuq il-parti l-bajda tal-għajn).
English: The active substance in Jetrea, ocriplasmin, is similar to human plasmin, a naturally occurring enzyme in the eye which is capable of breaking down proteins between the vitreous humour and the retina which are responsible for the adhesion, thereby reducing retinal swelling and improving vision.
Maltese: Is-sustanza attiva f'Jetrea, l-okriplasmina, hija simili għall-plasmina tal-bniedem, enzima preżenti b'mod naturali fl-għajn li kapaċi tkisser il-proteini bejn l-umur vitriju u r-retina li huma responsabbli mill-adeżjoni, b'hekk titnaqqas in-nefħa fir-retina u tittejjeb il-vista.
English: What are the risks associated with Jetrea?
Maltese: X'inhuma r-riskji assoċjati ma' Jetrea?
English: The recommended dose is 0.125 mg given as a single injection into the affected eye which should not be repeated.
Maltese: Id-doża rakkomandata hija 0.125 mg mogħtija b'injezzjoni waħda fl-għajn affettwata li ma għandhiex tiġi ripetuta.
English: The ophthalmologist may prescribe antibiotic eye drops before and after treatment with Jetrea to prevent eye infections.
Maltese: L-oftalomoloġista jista' jippreskrivi taqtir antibijotiku għall-għajn qabel u wara l-kura b'Jetrea biex jiġu evitati infezzjonijiet fl-għajn.
English: Other information about Jetrea
Maltese: Informazzjoni oħra dwar Jetrea
English: Studies have shown that Jetrea was effective in treating vitreomacular adhesion and it is therefore expected to be effective in preventing worsening of vision which may occur with untreated and progressive vitreomacular traction.
Maltese: Studji wrew li Jetrea kien effikaċi fil-kura ta' adeżjoni vitreomakulari u li għaldaqstant huwa mistenni li jkun effikaċi fil-prevenzjoni ta' tiħżin fi-vista li jista' jseħħ bi trazzjoni vitreomakulari mhux ittrattata u progressiva.
English: How does Jetrea work?
Maltese: Kif jintuża Jetrea?
English: It can only be obtained with a prescription and must be given by a qualified ophthalmologist (eye specialist) experienced in intravitreal injections (injections into the vitreous humour, the jelly-like material at the back of the eye).
Maltese: Jista' jinkiseb biss b'riċetta ta' tabib u jrid jingħata minn oftalmoloġista kkwalifikat (speċjalist tal-għajnejn) li jkollu l-esperjenza fl-injezzjonijiet intravitreali (injezzjonijiet fl-umur vitriju, il-materjal qisu ġelì fin-naħa ta' wara tal-għajn).
English: The procedure should be carried out under sterile conditions.
Maltese: Il-proċedura għandha ssir f'kundizzjonijiet sterili.
English: When the vitreous humour shrinks with aging, this strong attachment results in a pulling force on the retina, which causes retinal swelling and leads to blurred or distorted vision.
Maltese: Jidher li r-riskju ta' effetti sekondarji iktar serji bħal vista mnaqqsa li ma tkunx riversibbli, bidliet oħrajn fil-funzjoni retinali jew fl-istrutturi ta' appoġġ tal-lenti huwa żgħir.
English: Jetrea is a medicine used to treat adults with vitreomacular traction, an eye disease that can cause severe visual disturbance.
Maltese: Jetrea huwa mediċina li tintuża għall-kura ta' adulti bi trazzjoni vitreomakulari, marda fl-għajn li tista' tikkaġuna tfixkil serju fil-vista.
English: Vitreomacular traction is caused by vitreomacular adhesion in which the vitreous humour has an abnormally strong attachment to the central part of the retina (the light sensitive membrane at the back of the eye).
Maltese: It-trazzjoni virteomakulari hija kkaġunata minn adeżjoni vitreomakulari li fiha l-umur vitriju jaqbad b'saħħa anormali mal-parti ċentrali tar-retina (il-membrana ħafifa sensittiva fuq in-naħa ta' wara tal
English: How is Jetrea used?
Maltese: Kif jaħdem Jetrea?
English: 4 mg/40 mg tablet
Maltese: 4 mg/40 mg pillola
English: 0.10 g/1 g per 100 ml oral solution
Maltese: 0.10 g/1 g ta ' 100 ml soluzzjoni orali
English: Member State (in EEA)
Maltese: Stat Membru (filŻEE)
English: Annex I List of the names, pharmaceutical form(s), strength(s) of the medicinal product(s), route(s) of administration, marketing authorisation holder(s) in the member states
Maltese: Anness I Semmi l-isem (ijiet) formola (i) farmaċewtiku (i) forma (i) ta 'droga (i), irrotta (i) ta' kif jingħata, id-detentur tal-Awtorizzazzjoni fis-suq fl-Istati Membri
English: VASOBRAL, solution buvable en flacon
Maltese: VASOBRAL, soluzzjoni orali f'kunjett
English: VASOBRAL, comprimé sécable
Maltese: VASOBRAL, pillola mmarkata
English: Marketing Authorisaton Holder
Maltese: Awtorizzazzjoni detentur suq
English: Content Package size Withdrawal Period
Maltese: Kontenut Daqs talpakkett
English: MA (EU) number (Invented) name
Maltese: Numru MA (UE) Isem (ivvintat) Qawwa Għamla Farmaċewtika
English: What is Egranli?
Maltese: X'inhu Egranli?
English: 21 November 2014 EMA/705109/2014 EMEA/H/C/002637
Maltese: EMEA/H/C/002637
English: Egranli is a medicine that contains the active substance balugrastim.
Maltese: Egranli huwa mediċina li fiha s-sustanza attiva balugrastim.
English: Egranli was investigated in a main study in 304 breast cancer patients receiving chemotherapy, in which it was compared with another medicine containing a different long-acting G-CSF called pegfilgrastim.
Maltese: Egranli ġie investigat fi studju ewlieni fi 304 pazjenti tal-kanċer tas-sider li rċevew kimoterapija, li fih tqabbel ma' mediċina oħra li fiha G-CSF differenti li jaħdem fit-tul imsejjaħ pegfilgrastim.
English: Withdrawal of the marketing authorisation application for Egranli (balugrastim) EMA/705109/2014
Maltese: (balugrastim) EMA/30237/2015
English: What was Egranli expected to be used for?
Maltese: Għal xiex kien mistenni li jintuża Egranli?